CUMULATIVE INDEX Volume 2, Numbers 1-12, Pages 1-144 June 2000-May 2001
CUMULATIVE INDEX Volume 2, Numbers 1-12, Pages 1-144 June 2000-May 2001
A
ABC transporters, multiple drug resistance, 2:19
Ac-PHSCN-NH2 peptide, prostate cancer 3:25
adenoviral vectors cancer treatment, 2:17 head and neck cancer, 2:17 lung cancer, 2:17
alcohol consumption, breast cancer, 10:105
aldo-keto reductase, polycyclic aromatic hydrocarbons, 4:41
androgen ablation therapy, prostate cancer, 3:25
angiogenesis angiostatin, 11:117 anti-vascular epithelial growth factor, 11:117 heparanase, 7:73 ionizing radiation, 11:117 isocoumarin NM-3, 11:117 Lewis lung carcinoma, 11:117 VE-cadherin, 11:125
angiostatin ionizing radiation, 11:117 Lewis lung carcinoma, 11:117
antiangiogenic therapy and photodynamic therapy, 8:81 VE-cadherin, 11:125
anti-vascular epithelial growth factor, angiogenesis, 11:117 ionizing radiation, 11:117
Apo2L/TRAIL apoptosis, 9:101 ionizing radiation, 9:101
apoptosis Apo2L/TRAIL, 9:101 Bak, 2:17 Bcl-2 protein family, 1:1 DNA mismatch repair, 9:93 insulin-like growth factor, 1:1 ionizing radiation, 9:101 p53, 2:17, 9:93 tumor necrosis factor, 9:101
B
Bak apoptosis, 2:17 Bcl-2 protein family, 2:17 p53, 2:17
basement degradation, heparanase, 7:73
Bcl-2 protein family, apoptosis, 1:1 Bak, 2:17
Bcr/Abl, chronic myelogenous leukemia, 4:45
bone homeostasis osteoclastogenesis-inhibitory factor, 2:22 osteoprotegerin, 2:22
BRCA1, breast cancer, 10:105
breast cancer alcohol consumption, 10:105 BRCA1, 10:105 breast cancer resistance protein fumitremorgin C, 2:19 multiple drug resistance, 2:19 BRMS1, 5:57 estrogen hormones, 3:29 estrogen receptor a, 10:105, 12:133 low-penetrance susceptibility genes, 12:137 peroxisome proliferator-activated receptor g, 3:32 phenol sulfotransferases, 12:137 splicing variants, 12:133 sulfotransferases, 12:137
BRMS1, breast cancer, 5:57
butyrate, colonic epithelium, 1:7
C
cadherins, cellular adhesion, 1:5
cancer treatment, adenoviral vectors, 2:17
carboxylesterases, irinotecan, 7:80
cell cycle progression, polo-like kinase family, 12:140
cell cycle arrest cell adhesion, 1:5 colonic epithelium cells, 1:7
cell cycle regulation cadherins, 1:5 c-Myc, 4:37 cyclin-dependent kinases, 1:5 E-cadherin, 1:5
cell cycle progression, polo-like kinase family, 12:140
cell invasion, matrix metalloproteinases, 2:13
cell migration, matrix metalloproteinases, 2:13
cell survival, insulin-like growth factor, 1:1
cellular adhesion cadherins, 1:5 cell cycle regulation, 1:5 E-cadherin, 1:5
cellular differentiation c-Myc, 4:37 non-small cell lung cancer, 3:32 peroxisome proliferator-activated receptor g, 3:32
cellular stress response glutathione s-transferases, 6:65 reactive oxygen species, 6:65
c-Fes, chronic myelogenous leukemia, 4:45
chemosensitizing agents fumitremorgin C, 2:19 mitoxantrone, 2:19 multiple drug resistance, 2:19
chronic myelogenous leukemia Bcr/Abl, 4:45 c-Fes, 4:45 tyrosine kinases, 4:45
c-Myc cell cycle regulation, 4:37 cellular differentiation, 4:37 coding region instability determinant, 4:37
coding region instability determinant, c-Myc, 4:37
colon adenocarcinomas, irinotecan, 7:80
colon cancer colitis, 1:7 peroxisome proliferator-activated receptor g, 3:32
colonic epithelium butyrate, 1:7 short-chain fatty acids, 1:7
constitutively activated Akt, Ewing’s sarcoma, 1:1
cyclin-dependent kinases, cell cycle regulation, 1:5
cyclooxygenase-2 prostaglandins, 6:61 prostate cancer, 6:61
D
diagnostic tools, prostate cancer, 11:120
diet and prostate cancer, 6:61 and skin cancer, 8:87
DNA microarray analysis, mechanisms of drug resistance, 6:67
DNA mismatch repair apoptosis, 9:93 ionizing radiation, 9:93 p53, 9:93
drug resistance, multiple, and ABC transporters, 2:19
E
E-cadherin cell cycle regulation, 1:5 cellular adhesion, 1:5
endostatin angiogenesis, 11:117 ionizing radiation, 11:117
epidermal growth factor receptor family, overexpression in human cancers, 5:52
epithelial growth factor, angiogenesis, 11:117
estradiol breast cancer, 3:29 uterine cancer, 3:29
estrogen hormones breast cancer, 3:29 estradiol, 3:29 uterine cancer, 3:29
estrogen receptor a breast cancer, 10:105, 12:133 hypermethylation, 12:133 tumorigenesis, 12:133
Ewing’s sarcoma, constitutively activated Akt, 1:1
extracellular matrix degradation, heparanase, 7:73
extracellular matrix metalloproteinase
inducer tumor cell-derived collagenase stimulatory factor, 2:13 tumor progression, 2:13
F
fatty acids, colonic epithelium, 1:7
fumitremorgin C breast cancer resistance protein, 2:19 chemosensitizing agent, 2:19
G
genomic instability, peripheral blood leukocytes, 5:55
germline mutations, pheochromocytomas, 10:107
glutathione s-transferases multiple drug resistance, 6:65 reactive oxygen species, 6:65 stress kinases, 6:65 tumor cell survival, 6:65
H
head and neck cancer adenoviral vectors, 2:17 interleukin 4, 5:49 squamous cell carcinoma, 5:49
hematological malignancies leukemic transformation, 10:113 NUP98, 10:113
heparanase angiogenesis, 7:73 basement degradation, 7:73 extracellular matrix degradation, 7:73 tumor metastasis, 7:73
hormone independency, prostate cancer, 8:84
humeral hypercalcemia of malignancy, osteoprotegerin, 2:22 parathyroid hormone-related protein, 2:22
hypercalcemia osteoclastogenesis-inhibitory factor, 2:22 osteoprotegerin, 2:22
hypermethylation estrogen receptor a, 12:133 TPEF, 7:76
hypermutable phenotype, peripheral blood leukocytes, 5:55
hypoxia hypoxia-inducible factor, 8:81, 8:84 p53, 8:84 photodynamic therapy, 8:81 prostate cancer, 8:84
hypoxia-inducible factor hypoxia, 8:81, 8:84 p53, 8:84 photodynamic therapy, 8:81 prostate cancer, 8:84
I
insulin-like growth factor apoptosis, 1:1 cell survival, 1:1 receptor signaling, 1:1
interleukin 4 head and neck cancer, 5:49 squamous cell carcinoma, 5:49
ionizing radiation angiostatin, 11:117 and anti-vascular epithelial growth factor, 11:117 Apo2L/TRAIL, 9:101 apoptosis, 9:93, 9:101 DNA mismatch repair, 9:93 endostatin, 11:117 Lewis lung carcinoma, 11:117 and NM-3, 11:117 p53, 9:93 tumor necrosis factor, 9:101
irinotecan carboxylesterases, 7:80 colon adenocarcinomas, 7:80
isocoumarin NM-3, angiogenesis, 11:117
L
Lewis lung carcinoma angiogenesis, 11:117 angiostatin, 11:117 ionizing radiation, 11:117
leukemia, chronic myelogenous, 4:45
leukemic transformation, hematological malignancies, 10:113
leukemogenesis, NUP98, 10:113
liposarcoma, peroxisome proliferator- activated receptor g, 3:32
low molecular mass polypeptides adenoviral vectors, 2:17 major histocompatibility complex class I molecules, 10:109 polycyclic aromatic hydrocarbons, 4:41 renal cell carcinomas, 10:109
low-penetrance susceptibility genes, breast cancer, 12:137
lung cancer adenoviral vectors, 2:17 polycyclic aromatic hydrocarbons, 4:41
M
major histocompatibility complex
class I molecules low molecular mass polypeptides, 10:109 renal cell carcinomas, 10:109 transporters associated with antigen processing, 10:109 tumor escape, 10:109
maspin tumor suppressor genes, 8:90 urokinase-type plasminogen activator, 8:90
matrix metalloproteinase cell invasion, 2:13 cell migration, 2:13 in stromal cells 2:13, tumor growth, 2:13
methylation estrogen receptor a, 12:133 TPEF, 7:76 tumorigenesis, 7:76
mitosis, polo-like kinase family, 12:140
mitoxantrone chemosensitizing agent, 2:19 multiple drug resistance, 2:19
multiple drug resistance ABC transporters, 2:19 breast cancer resistance protein, 2:19 chemosensitizing agents, 2:19 DNA microarray analysis, 6:67 fumitremorgin C, 2:19 glutathione s-transferases, 6:65 mechanisms of resistance, 6:67 mitoxantrone, 2:19
multiple endocrine neoplasia type 2, pheochromocytomas, 10:107, 11:123 RET, 11:123
mutation frequency, peripheral blood leukocytes, 5:55
N
neurofibromatosis type 2 pheochromocytomas, 10:107, 11:23 RET, 11:123
NM-3 and ionizing radiation, 11:117 Lewis lung carcinoma, 11:117
non-small cell lung cancer cellular differentiation, 3:32 peroxisome proliferator-activated receptor g, 3:32
NUP98 hematological malignancies, 10:113 leukemogenesis, 10:113
O
osteoclastogenesis-inhibitory factor, bone homeostasis, 2:22 hypercalcemia, 2:22
osteoprotegerin bone homeostasis, 2:22 hypercalcemia, 2:22
P
p53 apoptosis, 9:93 Bak, 2:17 DNA mismatch repair, 9:93 hypoxia, 8:84 hypoxia-inducible factor, 8:84 ionizing radiation, 9:93
parathyroid hormone-related protein, humoral hypercalcemia of malignancy, 2:22
peripheral blood leukocytes genomic instability, 5:55 hypermutable phenotype, 5:55 mutation frequency, 5:55 single base substitution, 5:55
peroxisome proliferator-activated receptor g cellular differentiation, 3:32 liposarcoma, 3:32 non-small cell lung cancer, 3:32
phenol sulfotransferases, breast cancer, 12:137
phenotype, hypermutable, 5:55
pheochromocytomas germline mutations, 10:107 multiple endocrine neoplasia type 2, 10:107, 11:123 neurofibromatosis type 1, 10:107, 11:123 role of RET, 11:123 SDHD mutations, 10:107 von Hippel Lindau disease, 10:107, 11:123
photodynamic therapy and antiangiogenic therapy, 8:81 hypoxia, 8:81 hypoxia-inducible factor, 8:81 porphyrin photosensitizer, photofrin porfimer sodium, 8:81 vascular epithelial growth factor, 8:81
polo-like kinase family cell cycle progression, 12:140 mitosis, 12:140
polycyclic aromatic hydrocarbons aldo-keto reductase, 4:41 lung cancer, 4:41
polyunsaturated fatty acids prostate cancer, 6:61 skin cancer, 8:87, 9:97
prostaglandins cyclooxygenase, 6:61 and prostate cancer, 6:61
prostate cancer, Ac-PHSCN-NH2 peptide, 3:25 androgen ablation therapy, 3:25 cyclooxygenase-2, 6:61 diagnostic tools, 11:120 and diet, 6:61 hormone independency, 8:84 hypoxia, 8:84 hypoxia-inducible factor, 8:84 polyunsaturated fatty acids, 6:61 and prostaglandins, 6:61 prostate-specific genes, 11:120 PSGR overexpression, 11:120 serum prostate-specific antigen, 11:120
prostate-specific genes, PSGR, 11:120
PSGR overexpression, prostate cancer, 11:120
R
radiation, ionizing, 9:93, 9:101, 11:117
reactive oxygen species cellular stress response, 6:65 glutathione s-transferases, 6:65 stress kinase, 6:65 transcription factor activation, 6:65
receptor signaling, insulin-like growth factor 1, 1:1
renal cell carcinoma low molecular mass polypeptides, 10:109 major histocompatibility complex class I molecules, 10:109 transporters associated with antigen processing, 10:109 tumor escape, 10:109
RET multiple endocrine neoplasia type 2, 11:123 neurofibromatosis type 1, 11:123 pheochromocytomas, 11:123 von Hippel Lindau disease, 11:123
S
SDHD mutations, pheochromocytomas, 10:107
serum prostate-specific antigen, prostate cancer, 11:120
short-chain fatty acids, colonic epithelium, 1:7
single base substitution mutations, peripheral blood leukocytes, 5:55
skin cancer polyunsaturated fatty acids, 8:87, 9:97
splicing variants, breast cancer, 12:133
squamous cell carcinoma head and neck cancer, 5:49 interleukin 4, 5:49
stress kinase, reactive oxygen species, 6:65
stromal cells matrix metalloproteinase production, 2:13 tumor cells, 2:13
sulfotransferases, breast cancer, 12:137
T
TPEF methylation, 7:76 hypermethylation, 7:76
transcription factor activation, reactive oxygen species, 6:65
transporters associated with antigen
processing major histocompatibility complex class I molecules, 10:109 renal cell carcinomas, 10:109
tumor cell-derived collagenase stimulatory factor, extracellular matrix metalloproteinase inducer, 2:13
tumor cells, stromal cells, 2:13
tumor escape major histocompatibility complex class I molecules, 10:109 renal cell carcinomas, 10:109
tumor growth, matrix metalloproteinase, 2:13
tumor metastasis basement degradation, 7:73 extracellular matrix degradation, 7:73 heparanase, 7:73
tumor necrosis factor apoptosis, 9:101 ionizing radiation, 9:101
tumor progression, extracellular matrix metalloproteinase inducer, 2:13
tumor suppressor genes, maspin, 8:90
tumorigenesis estrogen receptor a, 12:133 hypermethylation, 7:76
tyrosine kinases, chronic myelogenous leukemia, 4:45
U
urokinase-type plasminogen activator, maspin, 8:90
uterine cancer, estrogen hormones, 3:29
V
vascular epithelial growth factor, photo-dynamic therapy, 8:81
VE-cadherin angiogenesis, 11:125 antiangiogenic therapy, 11:125
von Hippel Lindau disease, pheochromo-cytomas, 10:107, 11:12
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.